Biofrontera Inc. (BFRI) vs Zhengye Biotechnology Holding Limited (ZYBT)

Biofrontera Inc. and Zhengye Biotechnology Holding Limited are both Drug Manufacturers Specialty & Generic companies. Zhengye Biotechnology Holding Limited is the larger, with a market value of $40.1M against $17.8M — 2.3× the size. Across the 9 metrics below, Zhengye Biotechnology Holding Limited leads on 7 and Biofrontera Inc. on 2.

Valuation

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
P/E n/m — 20.14
P/S 0.33 — 2.25
P/B 2.56 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.34 n/m 2.56
Earnings yield (38.14%) — (2.99%)
Free cash flow yield (52.00%) 0.00% 0.00%

Profitability

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
Gross margin 79.25% — 53.94%
Operating margin (14.22%) — 0.00%
Net margin (13.78%) — 0.00%
Free cash flow margin (17.17%) 0.00% 0.00%
Return on equity (988.35%) 0.00% (0.40%)
Return on assets (28.80%) 0.00% (3.32%)
Return on invested capital (69.45%) 0.00% 0.00%

Growth

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% — 10.01%
EPS growth (last fiscal year) 67.70% (800.00%) —
Revenue growth, 5-year CAGR 17.21% — 6.74%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.24 0.05
Current ratio 1.18 1.14 2.31
Net debt to EBITDA 0.17 (0.51) 0.85

Dividend

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 — 0.00

Size

Metric BFRI ZYBT Drug Manufacturers Specialty & Generic median
Market cap 17.82m 40.13m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack